

CITATION REPORT

List of articles citing

Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials

DOI: 10.1016/0002-9343(83)91269-x
American Journal of Medicine, 1983, 75, 40-5.

Source: <https://exaly.com/paper-pdf/16391435/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
230	Clinical pharmacokinetics of labetalol. 1984 , 9, 157-67		44
229	Screening for antimalarial maculopathy in rheumatology clinics. 1985 , 291, 782-5		13
228	Antiprotozoal drugs. 1985 , 251-259		
227	The antiinflammatory activity of the immunomodulator Wy-18,251 (3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid). 1985 , 17, 53-9		25
226	Hydroxychloroquine treatment and the eye. 1985 , 14, 171-4		15
225	Management of rheumatoid arthritis. 1986 , 32, 1-74		3
224	The disposition and dynamics of labetalol in patients on dialysis. 1986 , 40, 462-8		22
223	Benefit-risk assessment of investigational drugs: current methodology, limitations, and alternative approaches. 1986 , 6, 286-303		8
222	The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. 1986 , 315, 727-30		122
221	Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. 1987 , 9, 1153-60		57
220	Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. 1987 , 317, 542-9		101
219	The prescribing of chloroquine and hydroxychloroquine by consultant rheumatologists in the UK. <i>Rheumatology</i> , 1987 , 26, 375-8	3.9	4
218	Thallium-201 stress imaging in hypertensive patients. 1987 , 10, 16-21		53
217	Hydroxychloroquine therapy in massive total doses without retinal toxicity. 1987 , 104, 139-44		73
216	Improved liquid-chromatographic assay of labetalol in plasma.. 1987 , 33, 1450-1452		8
215	Antimalarials in rheumatology: efficacy and safety. 1987 , 16, 206-21		69
214	Ocular effects and safety of antimalarial agents. <i>American Journal of Medicine</i> , 1988 , 85, 23-9	2.4	80

213	A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. 1989 , 48, 389-95		47
212	Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens. 1989 , 48, 542-6		19
211	Misconceptions about antimalarials. 1989 , 28, 648-9		2
210	Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. 1989 , 37, 583-627		36
209	Rheumatoid arthritis: current concepts and management, Part 2. 1990 , NS30, 49-54		1
208	Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. 1990 , 48, 509-19		22
207	Antimalarials in rheumatic diseases. 1990 , 4, 467-89		46
206	The risks of antimalarial retinopathy, azathioprine lymphoma and methotrexate hepatotoxicity during the treatment of rheumatoid arthritis. 1990 , 4, 193-206		4
205	Left ventricular systolic response to exercise in patients with systemic hypertension without left ventricular hypertrophy. 1990 , 65, 1204-8		11
204	Screening for hydroxychloroquine retinal toxicity: is it necessary?. 1990 , 4 (Pt 4), 572-6		53
203	Rational use of disease-modifying antirheumatic drugs. 1990 , 39, 19-37		23
202	Hypertension and cardiac disease in minorities. <i>American Journal of Medicine</i> , 1990 , 88, 3S-8S	2.4	14
201	Relation of obesity, high sodium intake, and eccentric left ventricular hypertrophy to left ventricular exercise dysfunction in essential hypertension. <i>American Journal of Medicine</i> , 1990 , 88, 477-85 ^{2.4}		57
200	Retinal damage due to antimalarial treatment. <i>American Journal of Medicine</i> , 1990 , 88, 553-4	2.4	3
199	Hydroxychloroquine retinopathy. 1991 , 112, 528-34		68
198	Quality monitor implementation for standards of care of the mechanically ventilated patient. 1991 , 2, 77-81		
197	Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy. 1991 , 34, 1116-24		67
196	Dose-response evaluation of oral labetalol in patients presenting to the emergency department with accelerated hypertension. 1991 , 20, 333-8		14

195	Treatment of Cutaneous Sarcoidosis With Chloroquine. 1991 , 127, 1034	72
194	Treatment of cutaneous lupus erythematosus. 1992 , 1, 351-6	7
193	Hydroxychloroquine: a guide to usage. 1992 , 3, 103-106	8
192	Monitoring for adverse effects from systemic drugs used in dermatology. 1992 , 26, 661-79	24
191	Antimalarial Agents and the Eye. 1992 , 10, 513-519	
190	The ocular safety of hydroxychloroquine. 1993 , 23, 62-7	60
189	Antimalarials for children: indications, toxicities, and guidelines. 1993 , 28, 764-70	35
188	Hydroxychloroquine, dosage parameters and retinopathy. 1993 , 2, 355-8	28
187	Ophthalmologic Safety Profile of Antimalarial Drugs. 1993 , 2, 17-19	20
186	The molecular basis of metal recognition by T cells. 1994 , 102, 398-401	116
185	Systemic lupus erythematosus--disease management. 1994 , 16, 281-94	2
184	Ocular toxicity of antimalarials in dermatology: a survey of current practice. 1994 , 131, 878-82	28
183	Exercise haemodynamics in the normotensive and the hypertensive subject. 1994 , 87, 275-87	34
182	Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. 1995 , 73, 73-7	28
181	Discoid lupus erythematosus. 1995 , 36, 3-10; quiz 11-2	18
180	Category III Symptom-Modifying Antirheumatic Drugs. 1995 , 3, 196-217	6
179	Disease-modifying antirheumatic drugs. Potential effects in older patients. 1995 , 7, 420-37	21
178	Retinopathy and antimalarial drugs [the British experience]. 1996 , 5, 70-72	8

177	Ophthalmologic considerations in using antimalarials in the United States. 1996 , 5, 73-74	24
176	The use of antimalarials in combination with other disease modifying agents in RA [the British experience. 1996 , 5, 50-58	6
175	Guidelines for monitoring drug therapy in rheumatoid arthritis. 1996 , 39, 723-731	200
174	New considerations in monitoring for hydroxychloroquine retinopathy. 1996 , 8, 99-104	2
173	Retinal toxicity in long term hydroxychloroquine treatment. 1996 , 55, 187-9	68
172	Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. 1996 , 5, 237-41	98
171	Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. 1997 , 56, 188-90	48
170	Eye damage from chloroquine as an antimalarial: misuse makes safe medicines unsafe. 1997 , 27, 10-2	
169	[Chloroquine-induced bull@ eye maculopathy without electrophysiologic changes]. 1997 , 210, 400-1	7
168	Usefulness of subnormal midwall fractional shortening in predicting left ventricular exercise dysfunction in asymptomatic patients with systemic hypertension. 1997 , 79, 1070-4	43
167	Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. 1997 , 40, 1482-6	191
166	Current concepts in monitoring patients on antimalarials. 1998 , 26, 101-3	14
165	[Maculopathy in long-term chloroquine therapy]. 1998 , 95, 186-7	3
164	Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. 1998 , 12 (Pt 6), 907-9	36
163	Long-term effectiveness of antimalarial drugs in rheumatic diseases. 1998 , 57, 582-7	72
162	Ocular toxicity and hydroxychloroquine: guidelines for screening. 1999 , 140, 3-7	61
161	Ocular toxicity of chloroquine among Thai patients. 1999 , 38, 934-7	10
160	The use of antimalarials in dermatology. 2000 , 11, 185-194	2

159	Chloroquine retinopathy and secondary trauma. 2000 , 12, 161-165	1
158	Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. 2000 , 30, 196-208	50
157	Medical Applications of Recombinant Proteins in Humans. 2000 , 3-26	
156	Hydroxychloroquine for the treatment of chronic graft-versus-host disease. 2000 , 6, 327-34	94
155	Cutaneous lupus erythematosus. 2001 , 20, 14-26	63
154	Antimalarials. 2001 , 19, 147-60, ix	55
153	Antimalarials. 2001 , 14, 143-153	1
152	Avaliaçã da toxicidade ocular por derivados da 4-aminoquinolona. 2002 , 65, 645-649	2
151	Le d'pistage de la toxicit'des antipalud'ens : notions courantes. 2002 , 37, 331-334	0
150	Screening for antimalarial toxicity: current concepts. 2002 , 37, 325-8, 331-4	11
149	Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. 2002 , 133, 649-56	83
148	Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. 2002 , 109, 1377-82	272
147	Liver abnormalities in rheumatic diseases. 2002 , 6, 933-46	26
146	Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcã. 2003 , 48, 863-4; author reply 864	4
145	Methotrexate versus chloroquine in the treatment of rheumatoid arthritis. 2003 , 6, 26-31	1
144	Uso de los antimalf'icos en dermatologã. 2003 , 18, 515-518	2
143	The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. 2003 , 110, 1321-6	195
142	Determinants of exercise capacity in hypertensive patients: new insights from tissue Doppler echocardiography. 2003 , 16, 564-9	18

141	Detecting chloroquine retinopathy: electro-oculogram versus colour vision. 2003 , 87, 902-8	34
140	Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. 2003 , 23, 503-12	47
139	Emerging therapies for graft-versus-host disease. 2003 , 8, 323-38	12
138	Factors associated with chloroquine-induced retinopathy in rheumatic diseases. 2004 , 13, 119-24	28
137	Factors associated with chloroquine-induced retinopathy in rheumatic diseases: comments on the article by Araiza-Casillas et al. 2004 , 13, 621	0
136	Protective effect of alpha-lipoic acid against chloroquine-induced hepatotoxicity in rats. 2004 , 24, 21-6	37
135	Dosing of antirheumatic drugs in renal disease and dialysis. 2004 , 10, 190-204	10
134	Avaliaçã dos efeitos adversos desencadeados pelo uso de difosfato de cloroquina, com ênfase na retinotoxicidade, em 350 doentes com lpus eritematoso. 2005 , 80, S275-S282	2
133	Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. 2005 , 110, 111-20	48
132	Antimalarials. 2005 , 347-372	
131	[Synthetic antimalarials]. 2005 , 132, 665-74	5
130	Cutaneous Lupus Erythematosus. 2005 ,	11
129	Hydroxychloroquine-induced retinopathy: a dermatologic perspective. 2006 , 7, 171-5	7
128	Abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retino-toxicity. 2006 , 20, 129-32	15
127	Retinal nerve fibre layer thickness measurements in patients using chloroquine. 2006 , 34, 130-6	22
126	Pediatric Hematopoietic Stem Cell Transplantation. 2006 ,	1
125	Cardiomyopathy related to antimalarial therapy with illustrative case report. 2007 , 107, 73-80	76
124	[Ocular toxicity due to 4-aminoquinoline derivatives]. 2007 , 70, 1046-51	8

123	Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. 2007 , 32, 579-84	2
122	[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]. 2007 , 104, 875-9	27
121	Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?. 2007 , 26, 1248-53	25
120	[Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up]. 2009 , 226, 891-6	3
119	Early diagnosis and treatment of discoid lupus erythematosus. 2009 , 22, 206-13	38
118	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. 2009 , 26, 273-93	19
117	Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. 2010 , 120, 251-64	15
116	Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. 2010 , 62, 775-84	184
115	Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment. 2010 , 21, 373-82	21
114	[Optical coherence tomography to evaluate peripapillary retinal nerve fiber layer in chloroquine patients]. 2010 , 73, 28-32	3
113	Treatment of cutaneous lupus erythematosus. 2010 , 19, 1125-36	33
112	Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. 2010 , 13, e11-5	17
111	Retinal disorders in northern Brazilian patients treated with chloroquine assessed by multifocal ERG. 2011 , 122, 77-86	3
110	CLINICAL CHARACTERISTICS OF HYDROXYCHLOROQUINE RETINOPATHY. 2011 , 12, 132-133	5
109	Safe use of antirheumatic agents in patients with comorbidities. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 771-93	2.4 4
108	Chloroquine cardiomyopathy - a review of the literature. 2013 , 35, 434-42	120
107	Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. 2013 , 2, 77-83	92
106	Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. 2013 , 155, 418-428.e1	53

105	Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. 2013 , 16, 47-55	6
104	The biological and clinical activity of anti-malarial drugs in autoimmune disorders. 2013 , 9, 45-62	27
103	Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. 2014 , 8, 1389-99	38
102	The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. 2014 , 8, 1401-7	11
101	Visual fields in a chloroquine treatment. 2014 , 59	
100	Hydroxychloroquine and Chloroquine Retinopathy. 2014 ,	25
99	Pharmacology of Chloroquine and Hydroxychloroquine. 2014 , 35-63	65
98	Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability. 2015 , 29, 299-304	19
97	A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. 2015 , 49, 317-26	77
96	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. 2015 , 23, 231-69	300
95	Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. 2015 , 358, 131-7	33
94	Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. 2016 , 8,	181
93	The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. 2016 , 166, ix-xi	18
92	Anti-malarials: Are There Benefits Beyond Mild Disease?. 2016 , 2, 1-12	5
91	Hair analysis of an unusual case of Chloroquine intoxication. 2016 , 19, 5-10	6
90	Hydroxychloroquine-related retinal toxicity. <i>Rheumatology</i> , 2016 , 55, 957-67	3.9 57
89	Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System. 2017 , 124, 604-608	12
88	Chloroquine Retinopathy under Inadequately Weight Adjusted Dosage: Early Detection by Multimodal Imaging. 2017 , 234, 543-545	2

87	Psychomotor Agitation Following Treatment with Hydroxychloroquine. 2017 , 4, 6	24
86	Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis. 2017 , 7, 15771	91
85	Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. 2018 , 27, 847-852	24
84	Autophagy Inhibition in Pancreatic Adenocarcinoma. 2018 , 17, 25-31	23
83	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. 2018 , 20, 133	26
82	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. 2018 , 38, 653-671	152
81	Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use. 2019 , 16, 100560	7
80	In-plane magnetic-field-induced quantum anomalous Hall plateau transition. 2019 , 100,	13
79	Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. 2019 , 28, 555-559	10
78	Chloroquine inhibits human retina pigmented epithelial cell growth and microtubule nucleation by downregulating p150. 2019 , 234, 10445-10457	5
77	Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection. 2019 , 108, 661-673	15
76	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. 2020 , 82, 709-722	12
75	Chloroquine differentially modulates coronary vasodilation in control and diabetic mice. 2020 , 177, 314-327	6
74	2019-nCoV: a worldwide concern and facts. 2020 , 31, 1-8	2
73	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. 2020 , 22, 223	5
72	Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. 2020 , 2020, 4582612	9
71	Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist@ perspective. 2021 , 28, 122-126	0
70	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. 2020 , 59, 1195-1216	18

69	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. 2020 , 13, 945-956	2
68	Antimalarials as Antivirals for COVID-19: Believe it or Not!. 2020 , 360, 618-630	14
67	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
66	Signal amplification by reversible exchange for COVID-19 antiviral drug candidates. 2020 , 10, 14290	4
65	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. 2020 , 22, 191	8
64	Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. 2020 , 11, 1167	8
63	Current targeted therapeutics against COVID-19: Based on first-line experience in China. 2020 , 157, 104854	27
62	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. 2020 , 35, 101735	71
61	Emergence of novel coronavirus and progress toward treatment and vaccine. 2020 , 30, e2116	6
60	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. 2020 , 30, 269-271	4099
59	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. 2020 , 16, 1678-1685	491
58	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. 2021 , 75, e13825	5
57	Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions. 2021 , 40, 2547-2557	13
56	Insight from nanomaterials and nanotechnology towards COVID-19. 2021 , 2, 100099	6
55	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. 2021 , 25, 441-452	2
54	Determining available strategies for prevention and therapy: Exploring COVID-19 from the perspective of ACE2 (Review). 2021 , 47,	3
53	SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. 2021 , 14, 1822-1829	1
52	SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. 2021 , 95, 107493	12

51	Hydroxychloroquine: Pharmacological, physicochemical aspects and activity enhancement through experimental formulations. 2021 , 63, 102512		0
50	Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. 2021 , 36, 2101-2110		0
49	Hydroxychloroquine for Primary Progressive Multiple Sclerosis. 2021 , 90, 940-948		5
48	Clinical Examples in Managing Patients Taking 4-Aminoquinolines. 2014 , 247-286		1
47	Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause. 2014 , 65-83		3
46	Hydroxychloroquine. 2005 , 81-92		5
45	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.		1
44	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <i>Rheumatology</i> , 2020 , 59, 3807-3816	3.9	10
43	Chloroquine inhibits Zika Virus infection in different cellular models.		11
42	Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection.		3
41	Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study.		29
40	Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice. 1991 , 65, 992-5		34
39	Hydroxychloroquine retinopathy: is screening necessary?. <i>BMJ: British Medical Journal</i> , 1998 , 316, 716-7		16
38	Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. 1998 , 102, 595-605		80
37	Optical coherence tomography in a patient with chloroquine-induced maculopathy. 2008 , 56, 511-3		23
36	Chloroquine and hydroxychloroquine in the context of COVID-19. 2020 , 9,		23
35	ANTIMALARIALS. 2002 , 74-80		
34	Lupus erythematosus: Eine Zwischenbilanz. 2003 , 328-338		

33	Retinal Toxicity of Systemic Medications. 2008 , 2213-2224		
32	Hydroxychloroquine-induced retinopathy*. 2012 , 180-184		
31	Screening for Hydroxychloroquine and Chloroquine Retinopathy. 2014 , 227-245		
30	Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy. 2014 , 133-154		
29	Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy. 2014 , 95-106		
28	Antiinflammatory and Immunosuppressive Drugs in the Treatment of Rheumatoid Arthritis. 1986 , 288-327		
27	Zytostatika, Immunsuppressiva, Immunmodulatoren aus dermatologischer Sicht. 1987 , 430-443		1
26	The Eye and the Skin. 1988 , 35-60		1
25	C. 1993 , 591-1166		
24	Systemic lupus erythematosus Disease management. 1995 , 151-164		
23	Treatment of lupus syndromes. <i>BMJ: British Medical Journal</i> , 1995 , 311, 264-5		
22	Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review.		
21	Different Cases of SARS-CoV-2 Infection and Its Impact on Health and Economy with Special Emphasis on Antiviral Drug Targets. <i>Journal of Pure and Applied Microbiology</i> , 2020 , 14, 799-816	0.9	
20	Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2020 , 1, 431-438	0.3	1
19	Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis. <i>Kliniceskaa Mikrobiologia I Antimikrobnaa Himioterapia</i> , 2020 , 22, 164-174	1.3	
18	Drug Induced Maculopathies. 2020 , 1-23		
17	Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown. <i>Indian Journal of Pharmacology</i> , 2020 , 52, 75-78	2.5	0
16	OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19. <i>Journal of Hearing Science</i> , 2020 , 10, 9-20	0.7	0

15	Sehstfungen. 2006 , 267-287		
14	Treatment: Disease-Modifying Therapies. <i>Rheumatic Disease Clinics of North America</i> , 1988 , 14, 223-243	2.4	9
13	Adverse reactions to chloroquine and amodiaquine as used for malaria prophylaxis: a review of the literature. <i>Canadian Family Physician</i> , 1987 , 33, 2644-9	0.9	12
12	[Chloroquine phosphate: therapeutic drug for COVID-19]. <i>Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University</i> , 2020 , 40, 586-594	0.5	1
11	Pharmacological approaches to the treatment of COVID-19 patients. <i>Journal of Translational Science</i> , 2020 , 6,	2.2	
10	Risk of hydroxychloroquine retinopathy in the community. <i>Rheumatology</i> , 2021 ,	3.9	0
9	Role of lipid Nanoparticles in COVID-19 inrepurposing drugs and vaccines. <i>Current Nanoscience</i> , 2021 , 17,	1.4	
8	A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial. <i>Trials</i> , 2021 , 22, 869	2.8	2
7	Pharmacological Modulation of Apoptosis and Autophagy in the Treatment of Pancreatic Cancer.. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022 ,	3.2	0
6	Table_1.xlsx. 2020 ,		
5	Table_2.xlsx. 2020 ,		
4	Drug Induced Maculopathies. 2022 , 3739-3761		
3	Redox aspects of cytotoxicity and anti-neuroinflammatory profile of chloroquine and hydroxychloroquine in serum-starved BV-2 microglia. <i>Toxicology and Applied Pharmacology</i> , 2022 , 116084 ^{4.6}		
2	Drug Induced Maculopathies. 2022 , 1-23		0
1	Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis. 2023 , 16, e252327		0